Metabolic disorders across hepatocellular carcinoma in Italy

F. Morisco; M. Guarino; M.R. Valvano; F. Auriemma; F. Farinati; E.G. Giannini; F. Ciccarese; F. Tovoli; G.L. Rapaccini; M. Di Marco; E. Caturelli; M. Zoli; F. Borzio; R. Sacco; G. Cabibbo; M. Felder; L. Benvengù; A. Gasbarrini; G. Svegliati Baroni; F.G. Foschi; E. Biasini; A. Masotto; R. Virdone; F. Marra; N. Caporaso; F. Trevisani; A. Sessa; F. Marafatto; G. Peserico; C. Pozzan; M. Brunacci; A. Moscatelli; G. Pellegatta; V. Savarino; P. Del Poggio; S. Olmi; N. de Matthaeis; C. Balsamo; E. Vavassori; P. Roselli; V. Lauria; G. Pelecca; V. Mismas; M. Rossi; S. Attardo; G. Cavani; A. Mega; E. Rinninella; A. Ortolani; A. Casadei Gardini

doi:10.1111/liv.13877

Metabolic disorders across hepatocellular carcinoma in Italy

F. Morisco, M. Guarino, M.R. Valvano, F. Auriemma, F. Farinati, E.G. Giannini, F. Ciccarese, F. Tovoli, G.L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, G. Cabibbo, M. Felder, L. Benvengù, A. Gasbarrini, G. Svegliati Baroni, F.G. FoschiE. Biasini, A. Masotto, R. Virdone, F. Marra, N. Caporaso, F. Trevisani, A. Sessa, F. Marafatto, G. Peserico, C. Pozzan, M. Brunacci, A. Moscatelli, G. Pellegatta, V. Savarino, P. Del Poggio, S. Olmi, N. de Matthaeis, C. Balsamo, E. Vavassori, P. Roselli, V. Lauria, G. Pelecca, V. Mismas, M. Rossi, S. Attardo, G. Cavani, A. Mega, E. Rinninella, A. Ortolani, A. Casadei Gardini

IRCCS Fondazione Policlinico Universitario A. Gemelli

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. Results: As compared with patients with 0-1 metabolic features, patients with 3-5 features showed lower percentage of HCC diagnosis on surveillance (P =.021), larger tumours (P =.038), better liver function (higher percentage of Child-Pugh class A [P =.007] and MELD

Original language	English
Pages (from-to)	2028-2039
Number of pages	12
Journal	Liver International
Volume	38
Issue number	11
DOIs	https://doi.org/10.1111/liv.13877
Publication status	Published - 2018

Keywords

alpha fetoprotein
antidiabetic agent
antihypertensive agent
antivirus agent
creatinine
hepatitis B surface antigen
lead
sodium
sorafenib, adult
aged
Article
body mass
cancer diagnosis
cancer staging
cancer survival
Child Pugh score
clinical evaluation
clinical feature
comparative study
controlled study
diabetes mellitus
diabetic patient
disease surveillance
female
human
hypercholesterolemia
hypertension
hypertriglyceridemia
Italy
liver cell carcinoma
liver function
liver metastasis
major clinical study
male
metabolic disorder
Model For End Stage Liver Disease Score
overall survival
portal vein thrombosis
prospective study
regional perfusion
retrospective study
sensitivity analysis
treatment indication
tumor volume

Access to Document

10.1111/liv.13877

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055329833&doi=10.1111%2fliv.13877&partnerID=40&md5=619cc3b72cb24493a34048722606d796

Cite this

Morisco, F., Guarino, M., Valvano, M. R., Auriemma, F., Farinati, F., Giannini, E. G., Ciccarese, F., Tovoli, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Cabibbo, G., Felder, M., Benvengù, L., Gasbarrini, A., Svegliati Baroni, G., ... Casadei Gardini, A. (2018). Metabolic disorders across hepatocellular carcinoma in Italy. Liver International, 38(11), 2028-2039. https://doi.org/10.1111/liv.13877

Metabolic disorders across hepatocellular carcinoma in Italy. / Morisco, F.; Guarino, M.; Valvano, M.R.; Auriemma, F.; Farinati, F.; Giannini, E.G.; Ciccarese, F.; Tovoli, F.; Rapaccini, G.L.; Di Marco, M.; Caturelli, E.; Zoli, M.; Borzio, F.; Sacco, R.; Cabibbo, G.; Felder, M.; Benvengù, L.; Gasbarrini, A.; Svegliati Baroni, G.; Foschi, F.G.; Biasini, E.; Masotto, A.; Virdone, R.; Marra, F.; Caporaso, N.; Trevisani, F.; Sessa, A.; Marafatto, F.; Peserico, G.; Pozzan, C.; Brunacci, M.; Moscatelli, A.; Pellegatta, G.; Savarino, V.; Del Poggio, P.; Olmi, S.; de Matthaeis, N.; Balsamo, C.; Vavassori, E.; Roselli, P.; Lauria, V.; Pelecca, G.; Mismas, V.; Rossi, M.; Attardo, S.; Cavani, G.; Mega, A.; Rinninella, E.; Ortolani, A.; Casadei Gardini, A.

In: Liver International, Vol. 38, No. 11, 2018, p. 2028-2039.

Research output: Contribution to journal › Article › peer-review

Morisco, F, Guarino, M, Valvano, MR, Auriemma, F, Farinati, F, Giannini, EG, Ciccarese, F, Tovoli, F, Rapaccini, GL, Di Marco, M, Caturelli, E, Zoli, M, Borzio, F, Sacco, R, Cabibbo, G, Felder, M, Benvengù, L, Gasbarrini, A, Svegliati Baroni, G, Foschi, FG, Biasini, E, Masotto, A, Virdone, R, Marra, F, Caporaso, N, Trevisani, F, Sessa, A, Marafatto, F, Peserico, G, Pozzan, C, Brunacci, M, Moscatelli, A, Pellegatta, G, Savarino, V, Del Poggio, P, Olmi, S, de Matthaeis, N, Balsamo, C, Vavassori, E, Roselli, P, Lauria, V, Pelecca, G, Mismas, V, Rossi, M, Attardo, S, Cavani, G, Mega, A, Rinninella, E, Ortolani, A & Casadei Gardini, A 2018, 'Metabolic disorders across hepatocellular carcinoma in Italy', Liver International, vol. 38, no. 11, pp. 2028-2039. https://doi.org/10.1111/liv.13877

Morisco, F. ; Guarino, M. ; Valvano, M.R. ; Auriemma, F. ; Farinati, F. ; Giannini, E.G. ; Ciccarese, F. ; Tovoli, F. ; Rapaccini, G.L. ; Di Marco, M. ; Caturelli, E. ; Zoli, M. ; Borzio, F. ; Sacco, R. ; Cabibbo, G. ; Felder, M. ; Benvengù, L. ; Gasbarrini, A. ; Svegliati Baroni, G. ; Foschi, F.G. ; Biasini, E. ; Masotto, A. ; Virdone, R. ; Marra, F. ; Caporaso, N. ; Trevisani, F. ; Sessa, A. ; Marafatto, F. ; Peserico, G. ; Pozzan, C. ; Brunacci, M. ; Moscatelli, A. ; Pellegatta, G. ; Savarino, V. ; Del Poggio, P. ; Olmi, S. ; de Matthaeis, N. ; Balsamo, C. ; Vavassori, E. ; Roselli, P. ; Lauria, V. ; Pelecca, G. ; Mismas, V. ; Rossi, M. ; Attardo, S. ; Cavani, G. ; Mega, A. ; Rinninella, E. ; Ortolani, A. ; Casadei Gardini, A. / Metabolic disorders across hepatocellular carcinoma in Italy. In: Liver International. 2018 ; Vol. 38, No. 11. pp. 2028-2039.

@article{74589035d7d34f39b0a32466c95f2c8f,

title = "Metabolic disorders across hepatocellular carcinoma in Italy",

abstract = "Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. Results: As compared with patients with 0-1 metabolic features, patients with 3-5 features showed lower percentage of HCC diagnosis on surveillance (P =.021), larger tumours (P =.038), better liver function (higher percentage of Child-Pugh class A [P =.007] and MELD ",

keywords = "alpha fetoprotein, antidiabetic agent, antihypertensive agent, antivirus agent, creatinine, hepatitis B surface antigen, lead, sodium, sorafenib, adult, aged, Article, body mass, cancer diagnosis, cancer staging, cancer survival, Child Pugh score, clinical evaluation, clinical feature, comparative study, controlled study, diabetes mellitus, diabetic patient, disease surveillance, female, human, hypercholesterolemia, hypertension, hypertriglyceridemia, Italy, liver cell carcinoma, liver function, liver metastasis, major clinical study, male, metabolic disorder, Model For End Stage Liver Disease Score, overall survival, portal vein thrombosis, prospective study, regional perfusion, retrospective study, sensitivity analysis, treatment indication, tumor volume",

author = "F. Morisco and M. Guarino and M.R. Valvano and F. Auriemma and F. Farinati and E.G. Giannini and F. Ciccarese and F. Tovoli and G.L. Rapaccini and {Di Marco}, M. and E. Caturelli and M. Zoli and F. Borzio and R. Sacco and G. Cabibbo and M. Felder and L. Benveng{\`u} and A. Gasbarrini and {Svegliati Baroni}, G. and F.G. Foschi and E. Biasini and A. Masotto and R. Virdone and F. Marra and N. Caporaso and F. Trevisani and A. Sessa and F. Marafatto and G. Peserico and C. Pozzan and M. Brunacci and A. Moscatelli and G. Pellegatta and V. Savarino and {Del Poggio}, P. and S. Olmi and {de Matthaeis}, N. and C. Balsamo and E. Vavassori and P. Roselli and V. Lauria and G. Pelecca and V. Mismas and M. Rossi and S. Attardo and G. Cavani and A. Mega and E. Rinninella and A. Ortolani and {Casadei Gardini}, A.",

note = "cited By 0",

year = "2018",

doi = "10.1111/liv.13877",

language = "English",

volume = "38",

pages = "2028--2039",

journal = "Liver International",

issn = "1478-3223",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "11",

}

TY - JOUR

T1 - Metabolic disorders across hepatocellular carcinoma in Italy

AU - Morisco, F.

AU - Guarino, M.

AU - Valvano, M.R.

AU - Auriemma, F.

AU - Farinati, F.

AU - Giannini, E.G.

AU - Ciccarese, F.

AU - Tovoli, F.

AU - Rapaccini, G.L.

AU - Di Marco, M.

AU - Caturelli, E.

AU - Zoli, M.

AU - Borzio, F.

AU - Sacco, R.

AU - Cabibbo, G.

AU - Felder, M.

AU - Benvengù, L.

AU - Gasbarrini, A.

AU - Svegliati Baroni, G.

AU - Foschi, F.G.

AU - Biasini, E.

AU - Masotto, A.

AU - Virdone, R.

AU - Marra, F.

AU - Caporaso, N.

AU - Trevisani, F.

AU - Sessa, A.

AU - Marafatto, F.

AU - Peserico, G.

AU - Pozzan, C.

AU - Brunacci, M.

AU - Moscatelli, A.

AU - Pellegatta, G.

AU - Savarino, V.

AU - Del Poggio, P.

AU - Olmi, S.

AU - de Matthaeis, N.

AU - Balsamo, C.

AU - Vavassori, E.

AU - Roselli, P.

AU - Lauria, V.

AU - Pelecca, G.

AU - Mismas, V.

AU - Rossi, M.

AU - Attardo, S.

AU - Cavani, G.

AU - Mega, A.

AU - Rinninella, E.

AU - Ortolani, A.

AU - Casadei Gardini, A.

N1 - cited By 0

PY - 2018

Y1 - 2018

N2 - Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. Results: As compared with patients with 0-1 metabolic features, patients with 3-5 features showed lower percentage of HCC diagnosis on surveillance (P =.021), larger tumours (P =.038), better liver function (higher percentage of Child-Pugh class A [P =.007] and MELD

AB - Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. Results: As compared with patients with 0-1 metabolic features, patients with 3-5 features showed lower percentage of HCC diagnosis on surveillance (P =.021), larger tumours (P =.038), better liver function (higher percentage of Child-Pugh class A [P =.007] and MELD

KW - alpha fetoprotein

KW - antidiabetic agent

KW - antihypertensive agent

KW - antivirus agent

KW - creatinine

KW - hepatitis B surface antigen

KW - lead

KW - sodium

KW - sorafenib, adult

KW - aged

KW - Article

KW - body mass

KW - cancer diagnosis

KW - cancer staging

KW - cancer survival

KW - Child Pugh score

KW - clinical evaluation

KW - clinical feature

KW - comparative study

KW - controlled study

KW - diabetes mellitus

KW - diabetic patient

KW - disease surveillance

KW - female

KW - human

KW - hypercholesterolemia

KW - hypertension

KW - hypertriglyceridemia

KW - Italy

KW - liver cell carcinoma

KW - liver function

KW - liver metastasis

KW - major clinical study

KW - male

KW - metabolic disorder

KW - Model For End Stage Liver Disease Score

KW - overall survival

KW - portal vein thrombosis

KW - prospective study

KW - regional perfusion

KW - retrospective study

KW - sensitivity analysis

KW - treatment indication

KW - tumor volume

U2 - 10.1111/liv.13877

DO - 10.1111/liv.13877

M3 - Article

VL - 38

SP - 2028

EP - 2039

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 11

ER -

Metabolic disorders across hepatocellular carcinoma in Italy

Abstract

Keywords

Access to Document

Fingerprint

Cite this